| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Biomedical Sciences, University "G. D’Annunzio," Ce.S.I., 66013 Chieti, Italy; and
DNA Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona 08036, Spain
1 Correspondence: Laboratorio di Medicina Molecolare, Dipartimento di Scienze Biomediche, Università "G. D’Annunzio," Ce.S.I., Via dei Vestini, 31, 66013 Chieti, Italy. E-mail: mromano{at}unich.it
Cyclooxygenase (COX) and lipoxygenase (LO) metabolic pathways are emerging as key regulators of cell proliferation and neo-angiogenesis. COX and LO inhibitors are being investigated as potential anticancer drugs and results from clinical trials seem to be encouraging. In this article we will review evidence of COX-2 and 5-LO involvement in cancer pathobiology, propose a model of integrated control of cell proliferation by these enzymes, and discuss the pharmacologic implications of this model.—Romano, M., Clària, J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.
Key Words: arachidonic acid • cancer • cyclooxygenase and lipoxygenase inhibitors • eicosanoids
This article has been cited by other articles:
|
|
 |
|
  S. Tavolari, M. Bonafe, M. Marini, C. Ferreri, G. Bartolini, E. Brighenti, S. Manara, V. Tomasi, S. Laufer, and T. Guarnieri Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade Carcinogenesis, February 1, 2008; 29(2): 371 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Horrillo, A. Planaguma, A. Gonzalez-Periz, N. Ferre, E. Titos, R. Miquel, M. Lopez-Parra, J. L. Masferrer, V. Arroyo, and J. Claria Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 778 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Ahn, G. Sethi, T.-H. Chao, S. T. C. Neuteboom, M. M. Chaturvedi, M. A. Palladino, A. Younes, and B. B. Aggarwal Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-{kappa}B regulated gene products Blood, October 1, 2007; 110(7): 2286 - 2295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 56S - 68S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Kunnumakkara, A. S. Nair, K. S. Ahn, M. K. Pandey, Z. Yi, M. Liu, and B. B. Aggarwal Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-{kappa}B activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis Blood, June 15, 2007; 109(12): 5112 - 5121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tan, J. Wu, X. Zhang, Y. Guo, J. Liu, T. Sun, B. Zhang, D. Zhao, M. Yang, D. Yu, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer Carcinogenesis, June 1, 2007; 28(6): 1197 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sethi, K. S. Ahn, M. K. Pandey, and B. B. Aggarwal Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-{kappa}B-regulated gene products and TAK1-mediated NF-{kappa}B activation Blood, April 1, 2007; 109(7): 2727 - 2735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Ahn, G. Sethi, and B. B. Aggarwal Simvastatin Potentiates TNF-{alpha}-Induced Apoptosis through the Down-Regulation of NF-{kappa}B-Dependent Antiapoptotic Gene Products: Role of I{kappa}B{alpha} Kinase and TGF-beta-Activated Kinase-1 J. Immunol., February 15, 2007; 178(4): 2507 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Gunter, F. Canzian, S. Landi, S. J. Chanock, R. Sinha, and N. Rothman Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1126 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, J. D. Potter, and C. M. Ulrich Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rossi, A. M. Acquaviva, F. Iuliano, R. Di Paola, S. Cuzzocrea, and L. Sautebin Up-regulation of prostaglandin biosynthesis by leukotriene C4 in elicited mice peritoneal macrophages activated with lipopolysaccharide/interferon-{gamma} J. Leukoc. Biol., October 1, 2005; 78(4): 985 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Titos, J. Claria, A. Planaguma, M. Lopez-Parra, A. Gonzalez-Periz, J. Gaya, R. Miquel, V. Arroyo, and J. Rodes Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells J. Leukoc. Biol., October 1, 2005; 78(4): 871 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Werz, I. Tretiakova, A. Michel, A. Ulke-Lemee, M. Hornig, L. Franke, G. Schneider, B. Samuelsson, O. Radmark, and D. Steinhilber Caspase-mediated degradation of human 5-lipoxygenase in B lymphocytic cells PNAS, September 13, 2005; 102(37): 13164 - 13169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Leopold and J. Loscalzo Oxidative Enzymopathies and Vascular Disease Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1332 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Goodman, E. D. Bowman, S. J. Chanock, A. J. Alberg, and C. C. Harris Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk Carcinogenesis, December 1, 2004; 25(12): 2467 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Y. Shin, W. K.K. Wu, Y.-N. Ye, W. H.L. So, M. W.L. Koo, E. S.L. Liu, J.-C. Luo, and C.-H. Cho Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2 Carcinogenesis, December 1, 2004; 25(12): 2487 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mao, I-H. Tsu, S. M. Dubinett, B. Adams, T. Sarafian, F. Baratelli, M. D. Roth, and K. J. Serio Modulation of Pulmonary Leukotriene B4 Production by Cyclooxygenase-2 Inhibitors and Lipopolysaccharide Clin. Cancer Res., October 15, 2004; 10(20): 6872 - 6878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hong, M. Bose, J. Ju, J.-H. Ryu, X. Chen, S. Sang, M.-J. Lee, and C. S. Yang Modulation of arachidonic acid metabolism by curcumin and related {beta}-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase Carcinogenesis, September 1, 2004; 25(9): 1671 - 1679. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
